Literature DB >> 26130472

Presentation and Diagnosis of Hypersensitivity to Platinum Drugs.

Joana Caiado1, Mariana Castells.   

Abstract

Hypersensitivity reactions (HSRs) to platinum drugs are increasing due to their extensive use in a wide variety of malignancies and the repeated exposures in patients with increased life expectancy. Understanding the incidence of HSR to platinum drugs and associated risk factors can help with the diagnosis and may provide protection against severe HSRs. A thorough clinical history with identification of the typical and atypical symptoms, the relationship with the platin administration, and the number of previous exposures are the key to the diagnosis. An elevated serum tryptase at the time of the HSR indicates that IgE and/or mast cells/basophils were involved in the HSR. Skin testing to platinum drugs is a highly sensitive and specific diagnostic tool, which helps provide risk stratification and management recommendations. Platinum specific IgE measurement and basophil activation test (BAT) are emerging as new diagnostic tools and in combination with skin testing can help support the diagnosis and the cross-reactivity between the three most commonly used platinum drugs, namely carboplatin, cisplatin, and oxaliplatin.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26130472     DOI: 10.1007/s11882-015-0515-3

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  104 in total

Review 1.  Drug allergy.

Authors:  David A Khan; Roland Solensky
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

2.  Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.

Authors:  Frédérique Maindrault-Goebel; Thierry André; Christophe Tournigand; Christophe Louvet; Nathalie Perez-Staub; Nora Zeghib; Aimery De Gramont
Journal:  Eur J Cancer       Date:  2005-09-09       Impact factor: 9.162

Review 3.  Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity.

Authors:  Ticha Limsuwan; Mariana C Castells
Journal:  Expert Opin Drug Saf       Date:  2010-01       Impact factor: 4.250

4.  Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.

Authors:  Mette Sprauten; Thomas H Darrah; Derick R Peterson; M Ellen Campbell; Robyn E Hannigan; Milada Cvancarova; Clair Beard; Hege S Haugnes; Sophie D Fosså; Jan Oldenburg; Lois B Travis
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

5.  Diagnosis and management of hypersensitivity reactions caused by oxaliplatin.

Authors:  T Herrero; P Tornero; S Infante; V Fuentes; M N Sánchez; M De Barrio; M L Baeza
Journal:  J Investig Allergol Clin Immunol       Date:  2006       Impact factor: 4.333

6.  Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up.

Authors:  Hege S Haugnes; George J Bosl; Hink Boer; Jourik A Gietema; Marianne Brydøy; Jan Oldenburg; Alv A Dahl; Roy M Bremnes; Sophie D Fosså
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

Review 7.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

8.  Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review.

Authors:  Brian H Kim; Thomas Bradley; Julia Tai; Daniel R Budman
Journal:  Oncology       Date:  2009-02-25       Impact factor: 2.935

9.  Desensitization with oxaliplatin in patients intolerant of carboplatin desensitization.

Authors:  Peter G Rose; Carol Metz; Nicolas Link
Journal:  Int J Gynecol Cancer       Date:  2014-11       Impact factor: 3.437

10.  Hypersensitivity reactions related to oxaliplatin (OHP).

Authors:  G Brandi; M A Pantaleo; C Galli; A Falcone; A Antonuzzo; P Mordenti; M C Di Marco; G Biasco
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

View more
  8 in total

1.  Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.

Authors:  Joyce F Liu; Mark F Brady; Ursula A Matulonis; Austin Miller; Elise C Kohn; Elizabeth M Swisher; David Cella; William P Tew; Noelle G Cloven; Carolyn Y Muller; David P Bender; Richard G Moore; David P Michelin; Steven E Waggoner; Melissa A Geller; Keiichi Fujiwara; Stacy D D'Andre; Michael Carney; Angeles Alvarez Secord; Katherine M Moxley; Michael A Bookman
Journal:  J Clin Oncol       Date:  2022-03-15       Impact factor: 50.717

2.  A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.

Authors:  Katherine LaVigne; David M Hyman; Qin C Zhou; Alexia Iasonos; William P Tew; Carol Aghajanian; Vicky Makker; Martee L Hensley; Jason Konner; Rachel N Grisham; Nicholas Cangemi; Krysten Soldan; David R Spriggs; Paul J Sabbatini; Roisin E OʼCearbhaill
Journal:  Int J Gynecol Cancer       Date:  2018-07       Impact factor: 3.437

3.  Nanoallergen platform for detection of platin drug allergies.

Authors:  Peter E Deak; Baksun Kim; Ather Adnan; Marina Labella; Leticia De Las Vecillas; Mariana Castells; Basar Bilgicer
Journal:  J Allergy Clin Immunol       Date:  2019-01-23       Impact factor: 10.793

4.  Cisplatin-induced sudden cardiac death with hemodynamic collapse: a severe adverse drug reaction: Case report.

Authors:  Silvijus Abramavicius; Marius Zemaitis; Vidas Pilvinis; Edmundas Kadusevicius
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

5.  Comparison of Hypersensitivity Reactions to Carboplatin Retreatment in Gynecologic Cancer Patients between One and Two Hour Infusions: a Randomized Trial Study

Authors:  Weerawich Pornwattanakrilert; Prapaporn Suprasert
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

Review 6.  Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers.

Authors:  Teodorikez Wilfox Jimenez-Rodriguez; Marlene Garcia-Neuer; Leila A Alenazy; Mariana Castells
Journal:  J Asthma Allergy       Date:  2018-06-20

Review 7.  Omalizumab for successful chemotherapy desensitisation: What we know so far.

Authors:  Roxana Silvia Bumbacea; Selda Ali; Sabina Loredana Corcea; Luiza Spiru; Cornelia Nitipir; Victor Strambu; Dragos Bumbacea
Journal:  Clin Transl Allergy       Date:  2021-12-13       Impact factor: 5.871

Review 8.  Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations.

Authors:  Mariana Castells
Journal:  Front Immunol       Date:  2017-11-08       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.